Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi - American Depositary Shares
(NQ:
SNY
)
57.75
+0.06 (+0.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
May 24, 2024
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Why Vaccine Stocks Rallied This Week
May 24, 2024
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?
Via
The Motley Fool
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
May 23, 2024
These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress.
Via
InvestorPlace
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
May 22, 2024
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.
Via
Benzinga
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
May 22, 2024
A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous...
Via
Benzinga
Why Novavax Stock More Than Doubled Today
May 10, 2024
A cloud of doubt hanging over the company just gave way to some sunshine.
Via
The Motley Fool
3 Biotech Stocks to Buy Now: May 2024
May 22, 2024
As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are.
Via
InvestorPlace
3 Things You Need to Know If You Buy Novavax Today
May 22, 2024
The vaccine maker's recovery story is looking brighter.
Via
The Motley Fool
ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
May 21, 2024
Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Roaring Kitty’s Rally Cry: 3 Meme Stocks to Pounce On Now
May 20, 2024
Jump into action with NVAX, HOOD and WKHS as top meme stocks to buy, offering the chance to capitalize on short squeezes and momentum.
Via
InvestorPlace
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
May 19, 2024
The biotech still hasn't lost momentum.
Via
The Motley Fool
Could Novavax Become the Next Moderna?
May 17, 2024
Sanofi believes in Novavax's vaccine strengths...
Via
The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
May 15, 2024
Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.
Via
Benzinga
Is DoubleVerify’s 39% Haircut a Buying Opportunity?
May 15, 2024
Digital advertising verification and measurement solutions provider DoubleVerify Holdings Inc. (NYSE: DV) shares took a 39% plunge on its Q1 2024 earnings
Via
MarketBeat
Topics
Artificial Intelligence
Fraud
Malware
Exposures
Artificial Intelligence
Information Security
Legal
3 Stocks Under $2 That Can Trade in Double Digits by 2025
May 15, 2024
These stocks under $2 are likely to surge higher as they represent companies with impending growth catalysts.
Via
InvestorPlace
Novavax Stock Just Tripled. Is It Too Late to Buy?
May 15, 2024
Novavax shares have soared and plummeted in recent years.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
May 14, 2024
Via
Benzinga
3 Cheap Biotech Stocks to Buy Now: May 2024
May 14, 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.
Via
InvestorPlace
Exposures
Product Safety
3 Meme Stocks That Are Likely to Crater in 2024
May 14, 2024
These are the meme stocks to avoid as they represent fundamentally weak companies with a sluggish growth outlook.
Via
InvestorPlace
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
May 13, 2024
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
NVAX Stock Alert: Novavax Just Hit a New 52-Week High
May 10, 2024
Novavax stock is heading higher on Friday as NVAX investors celebrate it reaching a new 52-week high following a deal with Sanofi.
Via
InvestorPlace
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
May 10, 2024
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal
May 10, 2024
NVAX stock is rising higher after the biotechnology company announced that it had signed a licensing deal with Sanofi.
Via
InvestorPlace
Biotech Rockets 125% On Sanofi Covid Vaccine Agreement
May 10, 2024
Novavax will receive as much as $1.2 billion as part of a Covid vaccine licensing deal with Sanofi.
Via
Investor's Business Daily
Exposures
COVID-19
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern
May 10, 2024
Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront payment of $500M, milestone opportunities, and revenue guidance update.
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.